Savara (NASDAQ:SVRA) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Savara (NASDAQ:SVRA – Free Report) from a hold rating to a sell rating in a research report report published on Saturday.

Other analysts have also issued research reports about the company. Oppenheimer started coverage on Savara in a report on Friday, April 24th. They issued an “outperform” rating and a $11.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Savara has a consensus rating of “Moderate Buy” and a consensus price target of $10.14.

Get Savara alerts:

View Our Latest Report on Savara

Savara Trading Down 0.2%

NASDAQ:SVRA opened at $5.37 on Friday. The stock has a fifty day simple moving average of $5.66 and a 200 day simple moving average of $5.48. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of -9.26 and a beta of 0.29. Savara has a 1-year low of $2.92 and a 1-year high of $7.01. The company has a quick ratio of 10.13, a current ratio of 10.13 and a debt-to-equity ratio of 0.21.

Savara (NASDAQ:SVRA – Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Sell-side analysts forecast that Savara will post -0.62 earnings per share for the current year.

Institutional Trading of Savara

Institutional investors have recently made changes to their positions in the business. Prudential Financial Inc. bought a new stake in shares of Savara in the 2nd quarter worth about $30,000. BNP Paribas Financial Markets increased its holdings in shares of Savara by 52.3% during the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after buying an additional 4,626 shares in the last quarter. Brevan Howard Capital Management LP acquired a new stake in shares of Savara during the second quarter worth approximately $33,000. Russell Investments Group Ltd. raised its stake in shares of Savara by 930.5% in the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after acquiring an additional 9,463 shares during the last quarter. Finally, CIBC Bancorp USA Inc. bought a new position in shares of Savara in the third quarter valued at approximately $44,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

About Savara

(Get Free Report)

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

Featured Stories

• Five stocks we like better than Savara
• Commodities Are Booming, But These 3 ETFs Tell Different Stories
• 3 Active ETFs Making Big Moves in August
• This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
• Birkenstock Beats the Skeptics—But Not on EPS

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.